- 现金
- 20418 元
- 精华
- 5
- 帖子
- 12767
- 注册时间
- 2013-12-29
- 最后登录
- 2024-5-15
|
Highlights from the Studies Presented:
Our clinical assets ARB-1740, AB-423 and preclinical assets ARB-880, ARB-1820 and ARB-168786, when used in combination with the 'NA and IFN' standard of care, demonstrate at least additive, and in some cases synergistic, anti-HBV activity.
Preclinical capsid assembly inhibitors ARB-880, ARB-1820 and ARB-168786 show potent and highly selective inhibition of HBV replication. Arbutus expects to nominate a 2nd generation capsid assembly development candidate this year.
These results continue to support Arbutus' combination strategy to develop an HBV cure. |
|